Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 5Phase 1/2 3Phase NA 2Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Syndrome, Transient 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Chromosome 5q Deletion Syndrome 1

Interventions

Cytarabine 13Daunorubicin 11Etoposide 7Filgrastim 5Peripheral Blood Stem Cell Transplantation 4Gemtuzumab 4valspodar 3Observation 3Mitoxantrone 3Busulfan 3sargramostim 2fludarabine phosphate 2aldesleukin 2Tretinoin 2Therapeutics 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Early Intervention, Educational 2Cyclophosphamide 2zosuquidar trihydrochloride 1midostaurin 1merphos 1laromustine 1etoposide phosphate 1dexamethasone acetate 1Whole-Body Irradiation 1Watchful Waiting 1Thioguanine 1Tacrolimus 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Congenital Abnormalities × Flow Cytometry × Clear all
NCT00322101 2014-10-31

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Fred Hutchinson Cancer Center

Phase 3 Completed
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Myeloproliferative Syndrome, Transient, Congenital Abnormalities, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡